About: Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.87 (-6.03%)
KLRS NASDAQ Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. share price
Atividade de preço de KLRS
Último preço
$ 1,870
Variação (24h)
-0,12 USD (6,03%)
Volume
25.40K
Volume (média 4 sem.)
-
Abertura
$ 1,99
Variação do dia
$ 1,87 - $ 1,99
Fechamento anterior
$ 1,99
Último negócio
23 Oct, 8:00 pm GMT+0
Atrasado
23 Oct, 8:00 pm GMT+0
KLRS price performance
Atrasado
23 Oct, 8:00 pm GMT+0
quote.marketSignals